The tobacco industry giant, Altria Group, has undergone a phase of fluctuating stock performance in recent years. While traders have welcomed instances of growth, the company's future prospects remain a topic of debate. Factors affecting Altria Group's stock consist of regulatory changes, market preferences, and the collective condition of the toba

The FDA has issued a warning about the risks of smuggled tirzepatide as the peptide therapeutics market grows rapidly. The market is expected to jump from $38 billion in 2023 to $106 billion by 2033, with an impressive 10.8% compound annual growth rate. Legitimate peptide medications have revolutionized modern medicine, with 102 FDA-approved therap